Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887
Last $65.64 USD
Change Today +1.18 / 1.83%
Volume 8.0M
As of 4:15 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - $70.54
52 Week Low
10/15/14 - $47.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

AstraZeneca, Bristol-Myers Squibb: Intellectual Property
Bristol-Myers 2015 Sales Forecast Hit by Dollar’s Strength
Stronger Dollar Punishes U.S. Earnings From P&G to DuPont
Fed, U.S. GDP, Greece, Apple, Amazon: Week Ahead Jan. 24-31
Fed, U.S. GDP, Greek Vote, Apple, Amazon: Week Ahead Jan. 24-31

bristol-myers squibb co (BMY) Related News

Company News: Alstom, GE, American Apparel, Bristol-Myers Squibb, Airbus, Starbucks, Square
Prudential Piles on the Corporate Pensions
White-Collar Workers Live Longer and the Gap Is Widening
What's the Dollar Value of Online Patient Chatter?

bristol-myers squibb co (BMY) Key Developments

Kyowa Hakko Kirin and Bristol-Myers Squibb Announces Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S

Kyowa Hakko Kirin Co. Ltd. and Bristol-Myers Squibb Company have entered into a clinical trial collaboration agreement to conduct a Phase 1/2 combination study with mogamulizumab, an anti-CCR4 antibody and Opdivo [2] (nivolumab), a PD-1 immune checkpoint inhibitor. The study, which will be conducted in the U.S., will focus on evaluating the safety, tolerability and anti-tumor activity of combining mogamulizumab and Opdivo as a potential treatment option for patients with advanced or metastatic solid tumors. Prior to this agreement, Kyowa Hakko Kirin, Bristol-Myers Squibband Ono Pharmaceutical Co. Ltd. entered into a clinical trial collaboration agreement to study the combination of mogamulizumab and Opdivo in Japan. Mogamulizumab and Opdivo are part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. The study will be conducted by Kyowa Hakko Kirin. About Mogamulizumab.

Bristol-Myers Squibb Company Announces Discontinuation of Phase III Renal Cell Carcinoma Study

Bristol-Myers Squibb Company has announced the discontinuation of an open-label, randomized Phase III study evaluating Opdivo versus everolimus in previously-treated patients with advanced or metastatic renal cell carcinoma, or RCC, based on an assessment conducted by the independent Data Monitoring Committee, or DMC, concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. CheckMate -025 investigators are being informed of the decision to stop the comparative portion of the trial. Bristol-Myers Squibb is working to ensure that eligible patients will be informed of the opportunity to continue or start treatment with Opdivo in an open-label extension as part of the company's commitment to providing patient access to Opdivo, and characterizing long-term survival. CheckMate -025 is a Phase III, open-label, randomized study of Opdivo versus everolimus in previously-treated patients with advanced or metastatic clear-cell renal cell carcinoma. The trial randomized 821 patients to receive either nivolumab 3 mg/kg intravenously every two weeks or everolimus 10 mg tablets by mouth daily until documented disease progression or unacceptable toxicity. The primary endpoint is overall survival. Secondary endpoints include objective response rate and progression-free survival.

Bristol-Myers Squibb Extends Compassionate Use Agreement for Opdivo with Italian Medicines Agency

The Italian Medicines Agency (AIFA) reported on 27 July 2015 that it had reached an agreement with Bristol-Myers Squibb (BMS) to extend a compassionate use agreement for the immuno-oncology drug Opdivo (nivolumab). Compassionate use agreements allow for the use of an unauthorised medicine for patients with a disease or condition for which there is no satisfactory authorised therapy. The agreement is intended to facilitate a medicine's availability while the treatment undergoes regulatory approval. BMS recently received a second approval from the European Commission for the use of Opdivo as a treatment option in patients with locally advanced or metastatic squamous (MS) non-small-cell lung cancer (NSCLC) following prior chemotherapy treatment. At the request of AIFA, Italy's Oncology Medical Association, and the Italian Association of Oncology Doctors, BMS launched the compassionate use programme for Opdivo on 21 April. Under the terms of the new agreement, the compassionate use programme will be extended until 18 September for all new patients diagnosed with NSCLC. This will ensure the continuation of current treatments that patients are on until the market authorisation comes into force in Italy.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $65.64 USD +1.18

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $70.01 USD -0.15
Allergan plc $331.15 USD +2.28
Eli Lilly & Co $84.51 USD -0.03
Medtronic PLC $78.39 USD +0.11
Novo Nordisk A/S kr398.40 DKK +1.20

Industry Analysis


Industry Average

Valuation BMY Industry Range
Price/Earnings 60.3x
Price/Sales 6.6x
Price/Book 7.1x
Price/Cash Flow 60.0x
TEV/Sales 5.8x

Sponsored Financial Commentaries

Sponsored Links

Bristol-Myers Squibb Co. Earnings Analysis: By the Numbers
7:01 am Bristol-Myers and AbbVie
10-Q for Bristol-Myers Squibb Co.
Is Bristol-Myers Squibb Outpacing Johnson & Johnson?
FDA Approves Daklinza
[Business Wire] - Bristol-Myers Squibb Company announced today that Daklinza™ , an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration .
Bristol-Myers Squibb
Bristol-Myers Shares Come With an Unhealthy Dose of Optimism
European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer(172KB)
[at noodls] - July 22, 2015 European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small ...
[at noodls] - July 22, 2015 CheckMate -025 (global clinical trial), a Pivotal Phase III Opdivo (nivolumab) Renal Cancer Trial Stopped Early (PRINCETON, NJ, July 20, 2015) - Bristol-Myers Squibb Company (NYSE:BMY) announced ...
Can Bristol-Myers
Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development
[Business Wire] - Bristol-Myers Squibb Company today announced additional Phase IIa proof-of-concept data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1.
Bristol-Myers says HIV drug gets FDA incentives
Bristol-Myers Squibb Receives Breakthrough Designation for HIV Treatment
Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients
[at noodls] - BMS-663068 is the first investigational antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells FDA Breakthrough Designation recognizes the need for new therapies for heavily treatment-experienced ...
9:02 am Bristol-Myers granted Breakthrough Therapy Designation from the FDA for BMS-663068 when used in combination with other antiretroviral agents for the treatment of HIV-1 infection in heavily treatment-experienced adult patients
Bristol-Myers cancer immunotherapy advances on two fronts
European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer
[at noodls] - First Immuno-Oncology agent approved in Europe for lung cancer, and the first major treatment advance in more than a decade Approval based on Checkmate -017, which showed nivolumab had a 41% reduction ...